radioimmunotherapy

Summary

Summary: Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

Top Publications

  1. ncbi High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
    T M Behr
    Department of Nuclear Medicine, Georg August University, Gottingen, Germany
    Cancer Res 59:2635-43. 1999
  2. ncbi Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    G A Wiseman
    Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Eur J Nucl Med 27:766-77. 2000
  3. ncbi Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer
    Jing Chen
    Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No 1095, Jiefang Dadao, 430030 Wuhan, People s Republic of China
    Cancer Lett 231:169-75. 2006
  4. ncbi Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
    Stefanie Sauer
    Department of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
    Blood 113:2265-74. 2009
  5. ncbi Doubly radiolabeled liposomes for pretargeted radioimmunotherapy
    M Mougin-Degraef
    Département de Recherche en Cancérologie, INSERM, U601, Universite de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France
    Int J Pharm 344:110-7. 2007
  6. ncbi Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6
    ROBERT T O'DONNELL
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA
    Prostate 50:27-37. 2002
  7. ncbi Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
  8. ncbi Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma
    Zhao Chong Zeng
    Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, P R China
    Eur J Nucl Med Mol Imaging 29:1657-68. 2002
  9. ncbi The radiation biology of radioimmunotherapy
    K L Dixon
    Department of Physics, The University of British Colombia, Canada
    Nucl Med Commun 24:951-7. 2003
  10. ncbi Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
    Eur J Cancer 44:366-73. 2008

Research Grants

  1. Targeted liposomal radiotherapy of malignant mesothelioma
    Jiang He; Fiscal Year: 2010
  2. Bispecific Antibody Engineering for AML RIT
    OLIVER W contact PRESS; Fiscal Year: 2010
  3. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2009
  4. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver W Press; Fiscal Year: 2010
  5. NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALS
    Donald Buchsbaum; Fiscal Year: 2001
  6. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
  7. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2007
  8. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver W Press; Fiscal Year: 2010
  9. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 1999
  10. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward A Neuwelt; Fiscal Year: 2010

Detail Information

Publications232 found, 100 shown here

  1. ncbi High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
    T M Behr
    Department of Nuclear Medicine, Georg August University, Gottingen, Germany
    Cancer Res 59:2635-43. 1999
    Recent studies suggest that radioimmunotherapy (RIT) with high-linear energy transfer (LET) radiation may have therapeutic advantages over conventional low-LET (e.g., beta-) emissions...
  2. ncbi Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    G A Wiseman
    Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Eur J Nucl Med 27:766-77. 2000
    ..The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or T(1/2), reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population...
  3. ncbi Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer
    Jing Chen
    Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No 1095, Jiefang Dadao, 430030 Wuhan, People s Republic of China
    Cancer Lett 231:169-75. 2006
    ..The results suggests that the radioimmunotherapy of intratumoral injection of 131I-Sc-7269-DMN may be safe and efficient for the treatment of liver cancer...
  4. ncbi Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
    Stefanie Sauer
    Department of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
    Blood 113:2265-74. 2009
    ..In 2 relapsed Hodgkin lymphoma patients(131)I-L19SIP radioimmunotherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma ..
  5. ncbi Doubly radiolabeled liposomes for pretargeted radioimmunotherapy
    M Mougin-Degraef
    Département de Recherche en Cancérologie, INSERM, U601, Universite de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France
    Int J Pharm 344:110-7. 2007
    The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters...
  6. ncbi Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6
    ROBERT T O'DONNELL
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA
    Prostate 50:27-37. 2002
    ..55 MBq;150 microCi) has resulted in durable responses. To make radioimmunotherapy (RIT) more effective, the radiation-enhancing drugs Taxol (paclitaxel) and Taxotere (docetaxel) were tested ..
  7. ncbi Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
    ..We have investigated the potential utility of pretargeted radioimmunotherapy using monoclonal antibody-streptavidin, immunoconjugates, and fusion proteins in combination with N-..
  8. ncbi Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma
    Zhao Chong Zeng
    Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, P R China
    Eur J Nucl Med Mol Imaging 29:1657-68. 2002
    It has previously been observed in animal studies that, at equivalent doses, radioimmunotherapy (RIT) is 2.5 times more effective than multiple fractions of external beam radiation therapy (EBRT) in inhibiting tumour growth...
  9. ncbi The radiation biology of radioimmunotherapy
    K L Dixon
    Department of Physics, The University of British Colombia, Canada
    Nucl Med Commun 24:951-7. 2003
    The treatment of cancer is a wide and varied field, encompassing many methods and modalities. Radioimmunotherapy is a technique which utilizes the ablative properties of radiation by delivering radioactive particles directly to the tumour ..
  10. ncbi Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
    Eur J Cancer 44:366-73. 2008
    ..This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas...
  11. ncbi High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
    Carol M Richman
    University of California Davis, Sacramento, California 95817, USA
    Clin Cancer Res 11:5920-7. 2005
    Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach...
  12. ncbi Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer
    R T O'Donnell
    Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, California 95816
    Clin Cancer Res 7:1561-8. 2001
    ..b>Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer...
  13. ncbi Feasibility of radioimmunotherapy of experimental pneumococcal infection
    E Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Antimicrob Agents Chemother 48:1624-9. 2004
    ..We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice...
  14. ncbi Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials
    Zhi-Nan Chen
    Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Int J Radiat Oncol Biol Phys 65:435-44. 2006
    ..0001 or p = 0.0019). CONCLUSION: Iodine (131I) metuximab injection is safe and active for HCC patients...
  15. ncbi Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy
    Jason L J Dearling
    Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, University College London, London, UK
    Clin Cancer Res 13:1903-10. 2007
    The efficacy of solid tumor radioimmunotherapy is reduced by heterogeneous tumor distribution of the radionuclide, with dose mainly deposited in the normoxic region and by the relative radioresistance of hypoxic tumor cells...
  16. ncbi Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109, USA
    Blood 101:2340-8. 2003
    ..These lymphoma xenograft data suggest that pretargeted radioimmunotherapy using either anti-CD20 or anti-CD45 conjugates is highly effective and minimally toxic.
  17. ncbi Editorial: what ails solid tumor radioimmunotherapy?
    Chaitanya Divgi
    Cancer Biother Radiopharm 21:81-4. 2006
  18. ncbi Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection
    Ekaterina Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Infect Dis 193:1427-36. 2006
    The usefulness of radioimmunotherapy (RIT) for infectious diseases was recently demonstrated for several fungal and bacterial infections, but the mechanisms by which RIT is effective against microbes are uncertain.
  19. ncbi A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies
    Yukang Lin
    The Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Cancer Res 66:3884-92. 2006
    ..We now show the superiority of pretargeted radioimmunotherapy (PRIT) compared with conventional radioimmunotherapy using a recombinant tetravalent single-chain Ab-..
  20. ncbi Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells
    Claudia Friesen
    University Children's Hospital, Prittwitzstrasse 43, 89075 Ulm, Germany
    Eur J Nucl Med Mol Imaging 30:1251-61. 2003
    Beta-irradiation used for systemic radioimmunotherapy (RIT) is a promising treatment approach for high-risk leukaemia and lymphoma...
  21. ncbi Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis
    Karin Knogler
    Center for Radiopharmaceutical Science, ETH PSI USZ, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
    Clin Cancer Res 13:603-11. 2007
    ..We examined the tumor-targeting and therapeutic effects of (67)Cu-labeled single amino acid mutant forms of anti-L1 monoclonal antibody chCE7 in nude mice with orthotopically implanted SKOV3ip human ovarian carcinoma cells...
  22. ncbi Rationales, evidence, and design considerations for fractionated radioimmunotherapy
    Gerald L DeNardo
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
    Cancer 94:1332-48. 2002
    ..used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies...
  23. ncbi Model prediction of treatment planning for dose-fractionated radioimmunotherapy
    Sui Shen
    Department of Radiation Oncology, University of Alabama at Birmingham, 35294, USA
    Cancer 94:1264-9. 2002
    Clinical trials of radioimmunotherapy (RIT) often use dose fractionation to reduce marrow toxicity. The dosing scheme can be optimized if marrow and tumor cell kinetics following radiation exposure are known.
  24. ncbi Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
    Shankar Vallabhajosula
    Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
    Clin Cancer Res 11:7195s-7200s. 2005
    Bone marrow is the dose-limiting organ in radioimmunotherapy. Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose...
  25. ncbi Engineered single chain antibody fragments for radioimmunotherapy
    A Huhalov
    Cancer Research UK Imaging and Targeting Group, Department of Oncology, Royal Free and University College Medical School, Royal Free Campus London, United Kingdom
    Q J Nucl Med Mol Imaging 48:279-88. 2004
    An ideal molecule to deliver radioimmunotherapy (RIT) would be target specific and have prolonged residence time at high concentrations in the tumour with rapid clearance from normal tissues. It would also be non-immunogenic...
  26. ncbi The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice
    Rébécca Phaeton
    Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA
    Cancer 116:1067-74. 2010
    ..The authors of this report recently demonstrated the efficacy of radioimmunotherapy (RIT) targeting viral oncoprotein E6 in the treatment of experimental cervical cancer...
  27. ncbi A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas
    Tim Meyer
    UCL Cancer Institute, University College London, United Kingdom
    Clin Cancer Res 15:4484-92. 2009
    In preclinical models, radioimmunotherapy with (131)I-A5B7 anti-carcinoembryonic antigen (CEA) antibody ((131)I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone...
  28. ncbi A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases
    Yonggang Lv
    Department of Biomedical Engineering, The City College of New York, New York, New York 10031, USA
    J Nucl Med 50:1324-31. 2009
    b>Radioimmunotherapy can effectively treat leptomeningeal metastases when radiolabeled antibodies are administered into the cerebrospinal fluid (CSF)...
  29. ncbi Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas
    W Debinski
    Department of Surgery, Pennsylvania State University, College of Medicine, Hershey 17033 0850, USA
    Clin Cancer Res 5:3143s-3147s. 1999
    ....
  30. ncbi PET/CT Imaging and Radioimmunotherapy of Prostate Cancer
    Kirsten Bouchelouche
    PET and Cyclotron Unit, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, Denmark
    Semin Nucl Med 41:29-44. 2011
    ..Prostate cancer represents an attractive target for radioimmunotherapy (RIT) for several reasons, including pattern of metastatic spread (lymph nodes and bone marrow, sites with ..
  31. ncbi Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
    Scott T Tagawa
    Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
    Cancer 116:1075-83. 2010
    ..Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy.
  32. ncbi Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6
    Rébécca Phaeton
    Department of Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY, USA
    Cancer Biol Ther 10:1041-7. 2010
    ..b>Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated ..
  33. ncbi FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study
    E Lopci
    Nuclear Medicine Department, University Hospital S Orsola Malpighi, Bologna, Italy
    Ann Oncol 21:1877-83. 2010
    ..is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL)...
  34. ncbi Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection
    Ruth A Bryan
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Infect Dis 202:633-7. 2010
    b>Radioimmunotherapy (RIT) prolongs the survival of mice infected with Cryptococcus neoformans. To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice intravenously with either nonmelanized or melanized C...
  35. ncbi Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma
    Peter L Roberson
    Department of Radiation Oncology, University of Michigan, 519 W William St, Argus I, Ann Arbor, MI 48103 4943, USA
    Eur J Nucl Med Mol Imaging 38:874-83. 2011
    ..Treatment with tositumomab and (131)I-tositumomab anti-CD20 radioimmunotherapy (BEXXAR) yields a cold antibody antitumor response (cold protein effect) and a radiation response...
  36. ncbi Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors
    Fares Al-Ejeh
    Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, South Australia, Australia
    PLoS ONE 4:e4630. 2009
    ..inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 ((90)Y)-radio-conjugates of a monoclonal antibody, ..
  37. ncbi Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells
    Ruth A Bryan
    Departments of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Antimicrob Agents Chemother 53:1679-82. 2009
    We investigated the utility of radioimmunotherapy (RIT) in the treatment of experimental cryptococcal infection with high-inoculum and the possibility of RIT treatment selecting for fungal cells with radiation-resistant phenotypes...
  38. ncbi Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer
    A Murray
    Department of Medical Physics, Medical School, Queen's Medical Centre, Nottingham, United Kingdom
    J Nucl Med 42:726-32. 2001
    ..MUC1 mucin is overexpressed on bladder tumors and represents a useful target for radioimmunoscintigraphy and radioimmunotherapy. We report on the production and initial tracer studies of a 188Re-antibody complex directed against this ..
  39. ncbi Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes
    Ekaterina Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, 1695A Eastchester Road, Bronx, NY 10461, USA
    J Nucl Med 45:313-20. 2004
    ..One novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal antibodies (mAbs) labeled with radionuclides...
  40. ncbi Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models
    E Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Antimicrob Agents Chemother 48:1004-6. 2004
    We evaluated acute hematological and long-term pulmonary toxicity of radioimmunotherapy in murine models of Cryptococcus neoformans infection...
  41. ncbi Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy
    M G Steffens
    Department of Urology, University Hospital Nijmegen, The Netherlands
    Cancer Res 59:1615-9. 1999
    ..the intratumoral distribution of the antibody is highly heterogeneous, which may limit the efficacy of radioimmunotherapy. A number of highly dynamic physiological factors have been postulated that may contribute to heterogeneous ..
  42. ncbi Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors--a review of radiolabeling characteristics, quality control and in vitro stability studies
    N Iznaga-Escobar
    Center of Molecular Immunology, Havana, Cuba
    Appl Radiat Isot 54:399-406. 2001
    ..characteristics, methods for quality control of radioimmunoconjugates and in vitro stability for radioimmunotherapy of solid tumors...
  43. ncbi Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin
    Zhengsheng Yao
    Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3137-46. 2004
    PURPOSE: The use of an alpha emitter for radioimmunotherapy has potential advantages compared with beta emitters...
  44. ncbi Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8
    K Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:716-8. 2000
    ..Intrathecal antibody-based targeted therapies may have clinical potential for patients with leptomeningeal (LM) cancer...
  45. ncbi Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT
    Alexandra D Jensen
    Dept of Radiation, Oncology INF, Heidelberg Germany
    BMC Cancer 11:182. 2011
    ..Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and ..
  46. ncbi Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme
    Anand Veeravagu
    Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305 5484, USA
    Clin Cancer Res 14:7330-9. 2008
    ..The purpose of this study was to evaluate the efficacy of a novel 90Y-Abegrin radioimmunotherapeutic agent in murine xenograft glioblastoma models with noninvasive in vivo molecular imaging modalities...
  47. ncbi Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy
    M Dreyling
    Department of Medicine III, Grosshadern, Ludwig Maximilians University, Munich, Germany
    Ann Hematol 86:81-7. 2007
    b>Radioimmunotherapy (RIT) was approved for the treatment of relapsed or refractory CD20-positive follicular lymphoma (FL), subsequent to rituximab containing primary therapy...
  48. ncbi A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy
    Inga Buchmann
    Department of Nuclear Medicine, University Hospital, Ulm, Germany
    Eur J Nucl Med Mol Imaging 30:667-73. 2003
    b>Radioimmunotherapy (RIT) with radiolabelled monoclonal antibodies (mAbs) is an effective method of achieving myeloablation in leukaemia patients prior to stem cell transplantation (SCT)...
  49. ncbi Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases
    Ekaterina Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA
    Expert Opin Drug Deliv 2:1075-84. 2005
    ..b>Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a ..
  50. ncbi Copper-67 as a therapeutic nuclide for radioimmunotherapy
    Ilse Novak-Hofer
    Center for Radiopharmaceutical Science ETH-PSI-USZ, Paul Scherrer Institute, CH-5232 Villigen, Switzerland
    Eur J Nucl Med Mol Imaging 29:821-30. 2002
    The application of the beta particle-emitting nuclide 67Cu in radioimmunotherapy is reviewed. The production of the nuclide is outlined, and different production modes are discussed with an emphasis on cyclotron production...
  51. ncbi Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:1226-35. 2009
    Pretargeted radioimmunotherapy (PRIT) is designed to enhance the directed delivery of radionuclides to malignant cells...
  52. ncbi Psychological distress of patients undergoing intensified conditioning with radioimmunotherapy prior to allogeneic stem cell transplantation
    N Grulke
    University Clinic for Psychosomatic Medicine and Psychotherapy, Frauensteige 14a, D 89075 Ulm, Germany
    Bone Marrow Transplant 35:1107-11. 2005
    ..is a pilot study comparing the emotional distress of patients receiving an intensified conditioning regimen (radioimmunotherapy=RIT) with patients receiving conventional conditioning for allogeneic stem cell transplantation...
  53. ncbi (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy
    Bernard M Tijink
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1235-44. 2009
    ..A clinical radioimmunotherapy (RIT) trial with (131)I-L19-SIP was recently started...
  54. ncbi A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies
    Jeffrey Y C Wong
    City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
    Cancer Biother Radiopharm 21:88-100. 2006
    Previous radioimmunotherapy (RIT) clinical trials at this institution with (90)Y-labeled cT84.66 anti-CEA (carcinoembryonic antigen) evaluated the antibody conjugated to diethylenetriaminepentaacetic acid (DTPA)...
  55. ncbi Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Mark S Kaminski
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:7985-93. 2005
    ..To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab...
  56. ncbi Radioimmunotherapy for non-Hodgkin's lymphoma
    Christos Emmanouilides
    UCLA Medical Center, Los Angeles, CA 90095, USA
    Semin Oncol 30:531-44. 2003
    b>Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic approach...
  57. ncbi Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis
    George Sgouros
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Cancer Biother Radiopharm 23:74-81. 2008
    ....
  58. ncbi Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity
    Jörgen Elgqvist
    Department of Radiation Physics, The Sahlgrenska Academy at Goteborg University, SE 413 45 Goteborg, Sweden
    Nucl Med Biol 33:1065-72. 2006
    The aim of this study was to investigate the therapeutic efficacy and myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice...
  59. ncbi Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma
    John P Plastaras
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, 2 Donner Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Oncologist 13:655-6. 2008
  60. ncbi Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Health Phys 92:33-9. 2007
    ....
  61. ncbi Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread
    Cecilia Hindorf
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Biother Radiopharm 22:357-66. 2007
    ..Treatment efficacy could, therefore, depend on the radionuclide used. The aim of this study was to investigate dosimetry at a cellular level for three isotopes of radioiodine...
  62. ncbi Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
    Prostate 69:92-104. 2009
    ..and therapeutic efficacy of Lutetium-177 (177Lu) radiolabeled anti-Lewis Y monoclonal antibody hu3S193 radioimmunotherapy (RIT) in mice bearing prostate cancer xenografts...
  63. ncbi Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Leo I Gordon
    Division of Hematology/Oncology, Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Semin Oncol 30:23-8. 2003
    ..This treatment regimen requires a coordinated multidisciplinary approach. Oncologists play a leading role in selecting patients for (90)Y ibritumomab tiuxetan therapy and in prescribing and overseeing the treatment...
  64. ncbi Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Cancer Biother Radiopharm 20:185-8. 2005
    Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%...
  65. ncbi New developments in immunotherapy for non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Curr Oncol Rep 7:364-71. 2005
    ..Further studies of unlabeled and radiolabeled immunotherapies are ongoing in order to optimize their use for maximal clinical benefit...
  66. ncbi 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma
    Antonio J Grillo-Lopez
    Neoplastic and Autoimmune Diseases Research Institute, Rancho Santa Fe, CA 92067 3797, USA
    Semin Oncol 32:S44-9. 2005
    b>Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, San Diego, CA, and Schering AG, Berlin, Germany) was approved in the United States in 2002 for patients with relapsed or refractory, low-grade, follicular, or ..
  67. ncbi Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma
    Robert Marcus
    Addenbrooke's Hospital, Cambridge, UK
    Semin Oncol 32:S36-43. 2005
    ..Thus, there is a continuing need for novel therapeutic options. One such strategy is targeted radioimmunotherapy, which is an attractive approach because lymphoma cells are inherently sensitive to radiation...
  68. ncbi Development of 131I-tositumomab
    Valerie Lewington
    Royal Marsden Hospital, Sutton, UK
    Semin Oncol 32:S50-6. 2005
    ..Targeted treatment using radioimmunotherapy (RIT), radiolabeled monoclonal antibodies directed against tumor-specific antigens, is an attractive option ..
  69. ncbi Radioimmunotherapy of non-Hodgkin's lymphoma revisited
    David M Goldenberg
    J Nucl Med 46:383-4. 2005
  70. ncbi Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA
    Blood 112:830-5. 2008
    ..showed that rituximab pretreatment significantly reduced B-NHL targeting and tumor control by CD20-directed radioimmunotherapy (RIT), but had no impact on targeting CD45...
  71. ncbi Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
    M Carmen Hernandez
    Department of Radiation Oncology, Stanford University Medical Center, 269 Campus Drive West, Stanford, CA 94305, USA
    Int J Radiat Oncol Biol Phys 59:1274-87. 2004
    The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies...
  72. ncbi Bias reduction in correlation of radiation-absorbed dose with response
    Kenneth F Koral
    J Nucl Med 45:1271; author reply 1271-2. 2004
  73. ncbi Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin
    Manuel J Koppe
    Department of Surgery, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Nucl Med 45:1224-32. 2004
    Therapeutic efficacy in radioimmunotherapy depends, among other things, on the choice of the radionuclide...
  74. ncbi Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
    Jostein Dahle
    Department of Radiation Biology, The Norwegian Radium Hospital, Montebello, Oslo, Norway
    Int J Radiat Oncol Biol Phys 72:186-92. 2008
    ..To determine the relative biologic effects (RBE) of alpha-particle radiation from 227Th-rituximab and of beta-radiation from 90Y-tiuexetan-ibritumomab (Zevalin) compared with external beam X-radiation in the Raji lymphoma xenograft model...
  75. ncbi Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma
    Irene Ghobrial
    Mayo College of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 18:623-30; discussion 633-4, 637-8, 640. 2004
    The field of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma (NHL) has advanced significantly over the past decade, and several radioimmunoconjugates are being tested in clinical trials...
  76. ncbi Does health economics have an impact on non-Hodgkin's lymphoma patients' options?
    Andreas Otte
    Nucl Med Commun 29:748-9. 2008
  77. ncbi [Nuclear medicine and lymphoma]
    Alberto Fernández de Sevilla Ribosa
    Rev Esp Med Nucl 25:77-9. 2006
  78. ncbi A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma
    Ola Linden
    Department of Oncology, Lund University Hospital, Lund, Sweden
    Cancer Biother Radiopharm 20:457-66. 2005
    b>Radioimmunotherapy is limited by the absorbed dose to radiosensitive organs...
  79. ncbi Radioimmunotherapy for Non-Hodgkin's Lymphoma
    Arati V Rao
    Division of Medical Oncology and Division of Geriatrics, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710, USA
    Clin Med Res 3:157-65. 2005
    ..e., radioimmunotherapy (RIT) in patients with NHL...
  80. ncbi Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
    Christos Emmanouilides
    Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    Leuk Lymphoma 47:629-36. 2006
    ..The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients...
  81. ncbi Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate
    Jostein Dahle
    Department of Radiation Biology, Norwegian Radium Hospital, Oslo, Norway
    Blood 110:2049-56. 2007
    ..A particularly interesting approach is in radioimmunotherapy. However, alpha-emitting antibody conjugates have been difficult to exploit clinically due to the short half-..
  82. ncbi [Radioimmunotherapy for B-cell lymphoma]
    Kensei Tobinai
    Rinsho Ketsueki 47:463-70. 2006
  83. ncbi Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
    Ruby F Meredith
    Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL, USA
    Int J Radiat Oncol Biol Phys 66:S15-22. 2006
    ..Two radioimmunotherapy agents that target the CD20 antigen, (131)I-tositumomab and (90)Y-ibritumomab tiuxetan, have been approved ..
  84. ncbi Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
    J Nucl Med 47:716-25. 2006
    b>Radioimmunotherapy (RIT) of solid tumor is often limited in efficacy because of restrictions in achieved tumor dose...
  85. ncbi Cure of incurable lymphoma
    Gerald L DeNardo
    Radiodiagnosis and Therapy, Division of Hematology Oncology, University of California Davis Medical Center, Sacramento, CA, USA
    Int J Radiat Oncol Biol Phys 66:S46-56. 2006
    ..antibody (MAb) treatment is to conjugate radionuclides to the MAb to deliver systemic radiotherapy (radioimmunotherapy; RIT). The antigen, MAb, and its epitope can make a difference in the performance of the drug...
  86. ncbi [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas]
    X Setoain
    Medicina Nuclear, , Barcelona
    Rev Esp Med Nucl 25:55-68; quiz 69-70.. 2006
  87. ncbi [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]
    C Emmanouilides
    Division Haematology-Oncology, UCLA, Los Angeles, USA
    Rev Esp Med Nucl 25:42-54. 2006
    b>Radioimmunotherapy treatment for lymphoma is a novel targeted therapeutic approach...
  88. ncbi Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein
    Donald J Buchsbaum
    Department of Radiation Oncology, University of Alabama at Birmingham, Alabama 35294 6832, USA
    Clin Cancer Res 11:8180-5. 2005
    This study examined a pretarget radioimmunotherapy strategy for treatment of an i.p. tumor model (LS174T).
  89. ncbi Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma
    Edgardo S Santos
    Tulane Cancer Center, Tulane University Health Sciences Center, New Orleans, LA, USA
    Leuk Lymphoma 47:2453-76. 2006
    ....
  90. ncbi [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment]
    Peter de Nully Brown
    H S Rigshospitalet, Finsencenteret, Haematologisk Afdeling L 4042, og Universitetssjukhuset i Lund, Onkologisk Klinik, Sverige
    Ugeskr Laeger 167:3867-9. 2005
    b>Radioimmunotherapy in indolent NHL is a new and promising therapy which adds a new therapeutic tool to the treatment palette. Recent advantages in RIT are described and perspectives discussed.
  91. ncbi [New trends in non-Hodgkin's lymphoma therapy]
    Grzegorz Mazur
    Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Akademii Medycznej we Wrocławiu
    Postepy Hig Med Dosw (Online) 60:707-21. 2006
    ..Apart from monoclonal antibodies, radioimmunotherapy, and autologous stem cell transplantation, which are used as standard therapy for some lymphomas, new drugs ..
  92. ncbi Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
    Jodi V Mones
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 48:342-8. 2007
    b>Radioimmunotherapy (RIT) with tositumomab and iodine 131 tositumomab can produce durable and complete responses in relapsed/refractory low-grade Non-Hodgkin's lymphoma...
  93. ncbi Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma
    Roger M Macklis
    Cleveland Clinic Lerner College of Medicine and Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Radiat Oncol 17:176-83. 2007
    b>Radioimmunotherapy (RIT) represents a relatively new antibody-based radiopharmaceutical treatment for patients with various kinds of tumors...
  94. ncbi A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study
    Erin Cooney Qualter
    Division of Pediatric Heamtology and Blood and Marrow Transplantation, Medicine and Pathology, Columbia University, New York, New York 10032, and Children s Hospital of Philadelphia, PA, USA
    Clin Cancer Res 13:5652s-5660s. 2007
    ..There is no data on the safety and feasibility of 90Y-IT in refractory childhood CD20+ lymphoma...
  95. ncbi Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478
    Fook T Lee
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 11:7080s-7086s. 2005
    ..The effect of EGFR signaling abrogation by EGFR tyrosine kinase inhibitor on the efficacy of radioimmunotherapy has not been reported previously...
  96. ncbi Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA
    Cancer Biother Radiopharm 19:11-23. 2004
    ..Because radiolabeled anti-CD19 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data support the use of 90Y anti-CD19 antibodies in treating B-cell malignancies...
  97. ncbi Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:165-78. 2003
    ..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity...
  98. ncbi Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
    T Nordøy
    Department of Oncology, University Hospital of Tromsø, Tromsø, N 9038, Norway
    Clin Immunol 100:40-8. 2001
    ..No significant reduction in antibody concentrations to tetanus or measles could be detected. The data show that acquired humoral immunity against common antigens appears to be preserved despite a temporary loss of B-lymphocytes...
  99. ncbi Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I
    R Stein
    Garden State Cancer Center, Belleville NJ 07109, USA
    J Nucl Med 42:967-74. 2001
    ..CONCLUSION: (177)Lu-RS7 is an effective radioimmunoconjugate for radioimmunotherapy. With its radiophysical properties similar to those of (131)I, coupled with its facile and stable attachment ..
  100. ncbi Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice
    Iris Verel
    Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 44:1663-70. 2003
    Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the confirmation of tumor targeting and the accurate estimation of radiation dose delivery to both tumor and normal tissues...
  101. ncbi Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice
    Malik E Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    J Nucl Med 43:1507-29. 2002
    b>Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin's lymphoma (NHL)...

Research Grants83

  1. Targeted liposomal radiotherapy of malignant mesothelioma
    Jiang He; Fiscal Year: 2010
    ..Highly selective tumor location and targeting are needed. Our long term goal is to develop effective radioimmunotherapy (RIT) for human cancers by marrying radiotherapy with nanotechnology...
  2. Bispecific Antibody Engineering for AML RIT
    OLIVER W contact PRESS; Fiscal Year: 2010
    ..of this research proposal is to maximize the cure rate of AML using a novel approach employing pretargeted radioimmunotherapy (PRIT) with genetically engineered bispecific antibodies...
  3. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2009
    Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
  4. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver W Press; Fiscal Year: 2010
    ..The objective of this research proposal is to improve the cure rate of AML using radioimmunotherapy (RIT) targeting the CD45 cell antigen...
  5. NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALS
    Donald Buchsbaum; Fiscal Year: 2001
    ..The experiments described in this application will provide answers to these questions. These studies would establish the rationale for human clinical RIT trials in patients with Jp. cancer using HuCC49ACH2. ..
  6. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    ..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
  7. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2007
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  8. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver W Press; Fiscal Year: 2010
    ..The objective of this research proposal is to optimize radioimmunotherapy (RIT) of B cell lymphomas utilizing pretargeting amplification strategies to improve the efficacy and ..
  9. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 1999
    ..Antibodies have been conjugated to metal chelates for radioimmunotherapy and studied extensively in recent years, and are in clinical trials at various stages...
  10. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward A Neuwelt; Fiscal Year: 2010
    ..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
  11. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2009
    ..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
  12. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2009
    ..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
  13. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2007
    ....
  14. Foundations of Pretargeted Radioimmunotherapy
    KARL D WITTRUP; Fiscal Year: 2010
    Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
  15. Novel glutamate conjugates for radiotargeting PSMA
    John Babich; Fiscal Year: 2004
    The development of novel approaches for radioimmunoimaging and radioimmunotherapy is driven by the high incidence and mortality rate associated with prostate cancer in the United States...
  16. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2001
    ..pretargeting amplification strategies to improve the efficacy and decrease the toxicity of conventional radioimmunotherapy (RAIT)...
  17. Improved Tumor Radiotherapy by MORF pretargeting
    Donald Hnatowich; Fiscal Year: 2005
    Despite several decades of effort, conventional radioimmunotherapy of hematopoietic and especially solid tumors is still providing marginal results. As such, alternative methods of treating these diseases are needed...